We have written about a huge variety of different approaches to cancer research since 2006 but few are as intriguing as using pathogen-based approaches involving viruses or bacteria to stimulate or re-activate the immune system. After all, when such foreign bodies break through the physical barriers and enter the bloodstream, the immune system instantly springs into action to tackle them.
Can this knowledge be used effectively in the design of anti-cancer therapeutics?
We have seen some promising initial results with oncolytic viruses, but what about bacterial based approaches? Can a different approach to drug scaffolds yield improved results?
Here, we look through the window at a novel platform using immunotoxins in early development that may well pique a few people’s interest and offer our latest thought leader interview discussing the approach…